Skip to main content

Table 2 Clinical features at diagnosis of patients with myopathy related to systemic sclerosis

From: Aldolase predicts subsequent myopathy occurrence in systemic sclerosis

Type Antibody At baseline At diagnosis
    Aldolase
(0 to 7 U/L)
AST
(0 to 32 U/L)
ALT
(0 to 32 U/L)
CK
(0 to 160 U/L)
8MMT
(0 to 80)
Aldolase
(0 to 7 U/L)
AST
(0 to 32 U/L)
ALT
(0 to 32 U/L)
CK
(0 to 160 U/L)
EMG Thigh muscle RMI Muscular biopsy
1 dSSc ATA 16 38 12 34 66 19 172 49 800 + - +
2 dSSc ATA 9 35 20 11 60 9.7 58 28 234 + - +
3 lSSc ACA 15.8 36 24 25 64 40 86 32 100 - + +
4 lSSc ATA 23.5 25 31 31 55 9.3 53 25 364 + + +
5 lSSc ACA 29 55 54 18 68 37.2 962 22 1,180 + + +
6 dSSc ATA
PM-Scl
9.3 56 29 36 66 22.4 122 99 254 + + +
7 dSSc ATA
U3-RNP
16.2 54 14 21 68 17.8 109 52 271 + + +
8 lSSc ACA 13.6 50 16 19 64 24.8 173 96 40 + + ND
9 dSSc 0 11.6 14 15 14 69 9.1 57 20 28 + + ND
  1. + means the presence of abnormalities described as criteria of myositis according to the EMNC (5); ACA, Anti-centromere antibodiy; ATA, Anti-topoisomerase I antibody; CK, creatine kinase; dSSc, diffuse form of systemic sclerosis; all patients had antinuclear antibody positive; EMG, electromyography; lSSc, limited cutaneous form of systemic sclerosis; ND, not done; PM-Scl, anti- polymyositis-scleroderma antibody; RMI, resonance magnetic imaging; U3-RNP, Anti U3-RNP antibody; Yrs, years